Literature DB >> 28187983

Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits.

Jens Oellgaard1, Peter Gæde2, Peter Rossing3, Frederik Persson4, Hans-Henrik Parving5, Oluf Pedersen6.   

Abstract

In the present post hoc analyses we studied the impact of intensified, multifactorial treatment on renal outcomes in patients with type 2 diabetes and microalbuminuria enrolled in the Steno-2 Study. Outcome measures were progression to macroalbuminuria, decline in the glomerular filtration rate (GFR), and development of end stage renal disease (ESRD). In total, 160 patients with type 2 diabetes and microalbuminuria were recruited and assigned to conventional or intensified therapy targeting multiple risk factors. The mean duration of the intervention was 7.8 years after which all patients were offered intensified therapy over a total follow-up up to 21 years on albuminuria, GFR, ESRD and mortality. Progression to macroalbuminuria was significantly reduced in the intensive-therapy group with a hazard ratio of 0.51 [95% confidence interval 0.32, 0.84]. The decline in GFR was significantly different with 3.1 ml/min/year in the intensive-therapy group compared to 4.0 in the conventional-therapy group. Progression to ESRD trended towards a decreased hazard with an adjusted ratio in the intensive group of 0.36 [0.12, 1.05]. ESRD combined with death had a significantly reduced hazard ratio of 0.53 [0.35, 0.8]. Thus, intensified, multifactorial treatment slowed progression in nephropathy and renal function loss reducing the risk of ESRD.
Copyright © 2017 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  chronic kidney disease; diabetic nephropathy; end-stage renal disease; microalbuminuria; type 2 diabetes

Mesh:

Year:  2017        PMID: 28187983     DOI: 10.1016/j.kint.2016.11.023

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  28 in total

Review 1.  Aspects of Multicomponent Integrated Care Promote Sustained Improvement in Surrogate Clinical Outcomes: A Systematic Review and Meta-analysis.

Authors:  Lee Ling Lim; Eric S H Lau; Alice P S Kong; Melanie J Davies; Naomi S Levitt; Björn Eliasson; Carlos A Aguilar-Salinas; Guang Ning; Yutaka Seino; Wing Yee So; Margaret McGill; Graham D Ogle; Trevor J Orchard; Philip Clarke; Rury R Holman; Edward W Gregg; Juan José Gagliardino; Juliana C N Chan
Journal:  Diabetes Care       Date:  2018-06       Impact factor: 19.112

2.  Proposal of classification of "chronic kidney disease (CKD) with diabetes" in clinical setting.

Authors:  Munehiro Kitada; Daisuke Koya
Journal:  Diabetol Int       Date:  2019-04-29

3.  Screening and Recognition of Chronic Kidney Disease in VA Health Care System Primary Care Clinics.

Authors:  Shweta Bansal; Michael Mader; Jacqueline A Pugh
Journal:  Kidney360       Date:  2020-07-09

Review 4.  Antiplatelet agents for chronic kidney disease.

Authors:  Patrizia Natale; Suetonia C Palmer; Valeria M Saglimbene; Marinella Ruospo; Mona Razavian; Jonathan C Craig; Meg J Jardine; Angela C Webster; Giovanni Fm Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2022-02-28

5.  The Effects of Novel Antidiabetic Drugs on Albuminuria in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Authors:  Ya Luo; Kai Lu; Gang Liu; Jing Wang; Irakoze Laurent; Xiaoli Zhou
Journal:  Clin Drug Investig       Date:  2018-12       Impact factor: 2.859

Review 6.  A narrative review of new treatment options for chronic kidney disease in type 2 diabetes.

Authors:  Frederik Persson; Rikke Borg; Peter Rossing
Journal:  Ann Transl Med       Date:  2021-04

7.  The importance of addressing multiple risk markers in type 2 diabetes: Results from the LEADER and SUSTAIN 6 trials.

Authors:  Emilie H Zobel; Bernt Johan von Scholten; Tine W Hansen; Frederik Persson; Søren Rasmussen; Benjamin Wolthers; Peter Rossing
Journal:  Diabetes Obes Metab       Date:  2021-11-05       Impact factor: 6.408

Review 8.  Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.

Authors:  Clement Lo; Tadashi Toyama; Ying Wang; Jin Lin; Yoichiro Hirakawa; Min Jun; Alan Cass; Carmel M Hawley; Helen Pilmore; Sunil V Badve; Vlado Perkovic; Sophia Zoungas
Journal:  Cochrane Database Syst Rev       Date:  2018-09-24

Review 9.  New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors.

Authors:  Claire C J Dekkers; Ron T Gansevoort; Hiddo J L Heerspink
Journal:  Curr Diab Rep       Date:  2018-03-27       Impact factor: 4.810

10.  Characterization of the renal cortical transcriptome following Roux-en-Y gastric bypass surgery in experimental diabetic kidney disease.

Authors:  Meera Nair; William P Martin; Vadim Zhernovkov; Jessie A Elliott; Naomi Fearon; Hans Eckhardt; Janet McCormack; Catherine Godson; Eoin Patrick Brennan; Lars Fandriks; Neil G Docherty; Carel W le Roux
Journal:  BMJ Open Diabetes Res Care       Date:  2020-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.